Tony Silbert, wrote:

<Just my opinion, but I think the basic policy that the institution
shouldn't
<take on any research project that costs them money is reasonable and anyone
<desiring concessions should squirm and produce serious justifications.  I
<think a policy that relieves the investigator of this process is another
step
<backward in the battle to present indirect costs as _real_ costs.

Good point , well taken!  This is an educational issue which, unfortunately,
 has been ambiguous in giving mixed signals to faculty.   It's our role to
help correct that misinformation to the "reality challenged."

Diane Gilbert wrote:

<For those of you who do "negotiate" with companies, how
 <      do you justify to the federal auditors that you charged industry
 <      (separate from clinical trials) a lower rate than you do the feds?
 <     Being currently in the position outlined, general comments would also
 <      be greatly appreciated on this topic.  (I do fully appreciate and
 <      sympathize with the faculty position, but the thought of the
potential
 <      of jeopardizing the federal indirect cost rate restrains acting on
 <      that sympathy.)

Outside of changing wet diapers for a baby, few people look forward to or
actually appreciate change!!!    Industry has historically given small
amounts of support in a largely government sponsored research arena, for
which they felt little need to add additional administrative/facility
support.    Past practice reinforces this mind set, which now challenges
this tension in a new era of a completely different portfolio of sponsored
research.

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Gary P. Naegel
Administrator, Pharmacology
Yale School of Medicine
333 Cedar Street  P.O. 208066
New Haven, CT  06520-8066
(203) 785-4373
FAX: (203) 785-7670
xxxxxx@yale.edu